Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

Core Insights - Jade Biosciences, Inc. is presenting new preclinical safety and translational data for its lead investigational candidate, JADE101, at the ASN Kidney Week 2025 [1][7] - JADE101 is designed to selectively inhibit APRIL in patients with immunoglobulin A nephropathy (IgAN), a serious autoimmune disease [2][4] - The company is currently conducting a Phase 1 clinical trial for JADE101, with interim data expected in the first half of 2026 [2][5] Company Overview - Jade Biosciences is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases, with JADE101 as its lead candidate targeting APRIL [6] - The company also has a second development candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both in preclinical development [6] Product Details - JADE101 is a fully human monoclonal antibody with ultra-high binding affinity for APRIL, engineered for extended half-life, showing a serum half-life of approximately 27 days in preclinical studies [4] - The therapy aims for infrequent and convenient subcutaneous dosing, which is crucial for patients often diagnosed in young adulthood [4] Clinical Trial Information - A Phase 1 randomized, double-blind, placebo-controlled trial is ongoing to evaluate single ascending subcutaneous doses of JADE101 in healthy adult volunteers [5] - The trial aims to define dose and dosing interval selection for later-stage studies based on biomarker responses [5] Presentation Details - JADE101's preclinical safety profile and translational framework will be highlighted in two poster sessions during ASN Kidney Week 2025 [3][7] - Presentations will occur on November 8, 2025, with specific titles and presenters listed [3]